Assessment of Postvaccination Neutralizing Antibodies Response against SARS-CoV-2 in Cancer Patients under Treatment with Targeted Agents
The administration of a third dose of a vaccine against SARS-CoV-2 has increased protection against disease transmission and severity. However, the kinetics of neutralizing antibodies against the virus has been poorly studied in cancer patients under targeted therapies. Baseline characteristics and...
Main Authors: | Flora Zagouri, Alkistis Papatheodoridi, Michalis Liontos, Alexandros Briasoulis, Aimilia D. Sklirou, Efthymia Skafida, Oraianthi Fiste, Christos Markellos, Angeliki Andrikopoulou, Konstantinos Koutsoukos, Maria Kaparelou, Eirini Gkogkou, Ioannis P. Trougakos, Meletios-Athanasios Dimopoulos, Evangelos Terpos |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-09-01
|
Series: | Vaccines |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-393X/10/9/1474 |
Similar Items
-
SARS-CoV-2 Neutralizing Antibodies Kinetics Postvaccination in Cancer Patients under Treatment with Immune Checkpoint Inhibition
by: Evangelos Terpos, et al.
Published: (2022-06-01) -
Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP Inhibitors
by: Michalis Liontos, et al.
Published: (2021-10-01) -
CDK4/6 Inhibitors and Arthralgia: A Single Institution Experience
by: Angeliki Andrikopoulou, et al.
Published: (2021-06-01) -
Aromatase and CDK4/6 Inhibitor-Induced Musculoskeletal Symptoms: A Systematic Review
by: Angeliki Andrikopoulou, et al.
Published: (2021-01-01) -
Oral SERDs alone or in combination with CDK 4/6 inhibitors in breast cancer: Current perspectives and clinical trials
by: Kleoniki Apostolidou, et al.
Published: (2024-06-01)